Compare eBay Inc (EBAY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Sanofi SA — how do they compare? eBay Inc trades at $103.8 (market cap $47.17B), while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.2× eBay Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| EBAY | SNY | |
|---|---|---|
Market Cap | $47.17B | $104.30B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $52.34 |
52-Week Low | $79.41 | $41.33 |
Enterprise Value | $51.00B | $124.19B |
Dividend Yield | 1.17% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $107.71, down 3.81% on news that GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock shows bearish technical signals but maintains strong fundamentals with 18.57% net margins and consistent earnings beats. Recent Q2 results exceeded expectations with 14% GMV growth, though insider selling and takeover uncertainty create near-term pressure.
EBAY offers solid fundamentals with improving revenue guidance and attractive valuation multiples, but faces significant event risk from the potential GameStop deal collapse. The 11% upside to consensus price target suggests moderate bullish sentiment, though investors should monitor partnership developments and Q3 earnings for directional clarity.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
